Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has received an additional 180-day extension from Nasdaq to meet the Minimum Bid Price Requirement. The extension, granted on January 30, 2024, allows the company until July 29, 2024, to regain compliance with the $1 per share minimum bid price rule. Failure to meet this requirement within the extended period could lead to delisting, although the company would have the right to appeal such a decision. Heart Test Laboratories is considering measures, including a potential reverse stock split, to address the compliance issue. However, there is no certainty that the company will achieve compliance within the new timeframe. This development follows an initial notification from Nasdaq on August 2, 2023, regarding the company's non-compliance based on its stock's closing bid price over the preceding 30 business days.
Heart Test Laboratories, Inc., a company listed on The Nasdaq Stock Market, has received an additional 180-day extension from Nasdaq to meet the Minimum Bid Price Requirement. The extension, granted on January 30, 2024, allows the company until July 29, 2024, to regain compliance with the $1 per share minimum bid price rule. Failure to meet this requirement within the extended period could lead to delisting, although the company would have the right to appeal such a decision. Heart Test Laboratories is considering measures, including a potential reverse stock split, to address the compliance issue. However, there is no certainty that the company will achieve compliance within the new timeframe. This development follows an initial notification from Nasdaq on August 2, 2023, regarding the company's non-compliance based on its stock's closing bid price over the preceding 30 business days.
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 已获得纳斯达克的额外180天延期，以满足最低出价要求。延期于2024年1月30日批准，允许该公司在2024年7月29日之前重新遵守每股1美元的最低出价规则。在延长的期限内未能满足这一要求可能会导致退市，尽管该公司有权对此类决定提出上诉。心脏测试实验室正在考虑采取措施，包括可能的反向股票分割，以解决合规问题。但是，尚不确定该公司是否会在新的时间框架内实现合规。这一事态发展是在纳斯达克于2023年8月2日根据其股票在前30个工作日的收盘出价发出初步通知之后发生的，该通知涉及该公司的违规行为。
在纳斯达克股票市场上市的公司Heart Test Laboratories, Inc. 已获得纳斯达克的额外180天延期，以满足最低出价要求。延期于2024年1月30日批准，允许该公司在2024年7月29日之前重新遵守每股1美元的最低出价规则。在延长的期限内未能满足这一要求可能会导致退市，尽管该公司有权对此类决定提出上诉。心脏测试实验室正在考虑采取措施，包括可能的反向股票分割，以解决合规问题。但是，尚不确定该公司是否会在新的时间框架内实现合规。这一事态发展是在纳斯达克于2023年8月2日根据其股票在前30个工作日的收盘出价发出初步通知之后发生的，该通知涉及该公司的违规行为。
有用
没用
